Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


24.10.2022

2 BJU Int
1 BMC Urol
2 Br J Cancer
1 Cancer
1 Cancer Imaging
1 Cancer Res
2 Clin Cancer Res
1 Discov Oncol
1 Eur Radiol
4 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
1 J Nucl Med
2 J Urol
3 Lancet Oncol
2 Oncogene
1 Oncol Rep
2 PLoS One
1 Proc Natl Acad Sci U S A
2 Prostate
1 Ther Adv Urol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    BJU Int

  1. VAN DER SLOT MA, den Bakker MA, Tan TSC, Remmers S, et al
    NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.
    BJU Int. 2022;130:628-636.
    PubMed         Abstract available

  2. CUSSENOT O, Cancel-Tassin G, Comperat E, Benbouzid S, et al
    Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable?
    BJU Int. 2022;130:582-585.
    PubMed        


    BMC Urol

  3. LI Y, Shi H, Zhao Z, Xu M, et al
    Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).
    BMC Urol. 2022;22:162.
    PubMed         Abstract available


    Br J Cancer

  4. CROWLEY F, Mihalopoulos M, Gaglani S, Tewari AK, et al
    Prostate cancer in transgender women: considerations for screening, diagnosis and management.
    Br J Cancer. 2022 Oct 19. pii: 10.1038/s41416-022-01989.
    PubMed         Abstract available

  5. GLUD EN, Rasmussen M, Zhang Y, Mandrup OA, et al
    Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 x anti-PSMA bispecific design.
    Br J Cancer. 2022 Oct 15. pii: 10.1038/s41416-022-01994.
    PubMed         Abstract available


    Cancer

  6. TAN WP, Kotamarti S, Chen E, Mahle R, et al
    Oncological and functional outcomes of men undergoing primary whole gland cryoablation of the prostate: A 20-year experience.
    Cancer. 2022;128:3824-3830.
    PubMed         Abstract available


    Cancer Imaging

  7. ZHANG X, Hong H, Liang D
    The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer.
    Cancer Imaging. 2022;22:60.
    PubMed         Abstract available


    Cancer Res

  8. SJOSTROM M, Zhao SG, Levy S, Zhang M, et al
    The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
    Cancer Res. 2022 Oct 17:OF1-OF15. doi: 10.1158/0008-5472.CAN-22-1123.
    PubMed         Abstract available


    Clin Cancer Res

  9. VAISHAMPAYAN UN, Thakur A, Chen W, Deol A, et al
    Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Oct 18. pii: 709809. doi: 10.1158/1078-0432.CCR-22-1601.
    PubMed         Abstract available

  10. FENG E, Rydzewski NR, Zhang M, Lundberg A, et al
    Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Oct 19. pii: 709863. doi: 10.1158/1078-0432.CCR-22-2567.
    PubMed         Abstract available


    Discov Oncol

  11. SMITH AE, Muralidharan A, Smith MT
    Prostate cancer induced bone pain: pathobiology, current treatments and pain responses from recent clinical trials.
    Discov Oncol. 2022;13:108.
    PubMed         Abstract available


    Eur Radiol

  12. LIAO Z, Liu G, Ming B, Ma C, et al
    Evaluating prostate cancer bone metastasis using accelerated whole-body isotropic 3D T1-weighted Dixon MRI with compressed SENSE: a feasibility study.
    Eur Radiol. 2022 Oct 21. pii: 10.1007/s00330-022-09181.
    PubMed         Abstract available


    Eur Urol

  13. LOEHR A, Hussain A, Patnaik A, Bryce AH, et al
    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
    Eur Urol. 2022 Oct 12. pii: S0302-2838(22)02639.
    PubMed         Abstract available

  14. XU P, Chen C, Chen B, Bi E, et al
    Long-term Follow-up of Detaenial Sigmoid Neobladder Reconstruction for Paediatric Patients with Bladder and Prostate Rhabdomyosarcoma: Technique and Results from a Single High-volume Centre.
    Eur Urol. 2022;82:543-550.
    PubMed         Abstract available

  15. MARTINI A, Mottet N, Montorsi F, Necchi A, et al
    A Plea for Economically Sustainable Evidence-based Guidelines.
    Eur Urol. 2022;82:449-451.
    PubMed         Abstract available

  16. CARVALHO FLF, Mossanen M, Van Allen EM, Mouw KW, et al
    Reply to Yuxuan Song, Yiqing Du, and Tao Xu's Letter to the Editor re: Matthew Mossanen, Filipe L.F. Carvalho, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
    Eur Urol. 2022 Aug 6. pii: S0302-2838(22)02534.
    PubMed        


    Int J Cancer

  17. CATTRINI C, Messina C, Mennitto A, Di Maio M, et al
    Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)".
    Int J Cancer. 2022;151:2291-2292.
    PubMed        


    Int J Radiat Oncol Biol Phys

  18. CHRIST SM, Pohl K, Muehlematter UJ, Heesen P, et al
    Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study.
    Int J Radiat Oncol Biol Phys. 2022;114:596-602.
    PubMed         Abstract available


    J Clin Oncol

  19. MA TM, Sun Y, Malone S, Roach M 3rd, et al
    Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
    J Clin Oncol. 2022 Oct 21:JCO2200970. doi: 10.1200/JCO.22.00970.
    PubMed         Abstract available

  20. KIM JW, McKay RR, Radke MR, Zhao S, et al
    Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947.
    PubMed         Abstract available


    J Nucl Med

  21. PHELPS TE, Harmon SA, Mena E, Lindenberg L, et al
    Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
    J Nucl Med. 2022 Oct 20. pii: jnumed.122.264334. doi: 10.2967/jnumed.122.264334.
    PubMed         Abstract available


    J Urol

  22. PAUDEL R, Madan R, Qi J, Ferrante S, et al
    The Use and Short-term Outcomes of Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer Managed With Active Surveillance: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
    J Urol. 2022 Oct 13:101097JU0000000000003012. doi: 10.1097/JU.0000000000003012.
    PubMed         Abstract available

  23. HANSEN NF, Linscott JA, Hayn MH, Ryan ST, et al
    PSA testing behaviors for prostate cancer screening among U.S. immigrants: a cross-sectional analysis using the NHIS.
    J Urol. 2022 Oct 11:101097JU0000000000002993. doi: 10.1097/JU.0000000000002993.
    PubMed         Abstract available


    Lancet Oncol

  24. BUTEAU JP, Martin AJ, Emmett L, Iravani A, et al
    PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
    Lancet Oncol. 2022 Oct 14. pii: S1470-2045(22)00605.
    PubMed         Abstract available

  25. SHIOTA M
    Continuing enzalutamide with docetaxel in castration-resistant prostate cancer.
    Lancet Oncol. 2022 Oct 17. pii: S1470-2045(22)00614.
    PubMed        

  26. MERSEBURGER AS, Attard G, Astrom L, Matveev VB, et al
    Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
    Lancet Oncol. 2022 Oct 17. pii: S1470-2045(22)00560.
    PubMed         Abstract available


    Oncogene

  27. KIKUNO N, Shiina H, Urakami S, Kawamoto K, et al
    Retraction Note: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.
    Oncogene. 2022 Oct 19. pii: 10.1038/s41388-022-02501.
    PubMed        

  28. TAN Q, Liu Z, Gao X, Wang Y, et al
    Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.
    Oncogene. 2022;41:4754-4767.
    PubMed         Abstract available


    Oncol Rep

  29. SUN W, Li L, Du Z, Quan Z, et al
    [Corrigendum] Combination of phospholipase Cepsilon knockdown with GANT61 sensitizes castrationresistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.
    Oncol Rep. 2022;48.
    PubMed         Abstract available


    PLoS One

  30. KANAO K, Takahashi T, Umezawa Y, Okabe T, et al
    Efficacy of abiraterone acetate for high-risk hormone-naive metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
    PLoS One. 2022;17:e0276081.
    PubMed         Abstract available

  31. MAPANGA W, Norris SA, Craig A, Pumpalova Y, et al
    Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa.
    PLoS One. 2022;17:e0276050.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  32. SHEN T, Dong B, Meng Y, Moore DD, et al
    A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2205350119.
    PubMed         Abstract available


    Prostate

  33. ODERDA M, Albisinni S, Benamran D, Calleris G, et al
    Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
    Prostate. 2022 Oct 19. doi: 10.1002/pros.24449.
    PubMed         Abstract available

  34. SATAPATHY S, Das CK, Aggarwal P, Sood A, et al
    Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    Prostate. 2022 Oct 19. doi: 10.1002/pros.24450.
    PubMed         Abstract available


    Ther Adv Urol

  35. BHATTACHARYA I, Khandwala YS, Vesal S, Shao W, et al
    A review of artificial intelligence in prostate cancer detection on imaging.
    Ther Adv Urol. 2022;14:17562872221128791.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: